1. Urantide alleviates the symptoms of atherosclerotic rats in vivo and in vitro models through the JAK2/STAT3 signaling pathway
   Tu Wang et al, 2021, European Journal of Pharmacology CrossRef
2. Urantide prevents CCl4‑induced acute liver injury in rats by regulating the MAPK signalling pathway
   Ying Li et al, 2021, Molecular Medicine Reports CrossRef
3. Urotensin II: an inflammatory cytokine
   Shui-lin Sun et al, 2019, Journal of Endocrinology CrossRef
4. The peptide compound urantide regulates collagen metabolism in atherosclerotic rat hearts and inhibits the JAK2/STAT3 pathway
   Tu Wang et al, 2020, Molecular Medicine Reports CrossRef
5. Urantide attenuates myocardial damage in atherosclerotic rats by regulating the MAPK signalling pathway
   Juan Zhao et al, 2020, Life Sciences CrossRef
6. The UII/UT System Mediates Upregulation of Proinflammatory Cytokines through p38 MAPK and NF-κB Pathways in LPS-Stimulated Kupffer Cells
   Liang Ming Liu et al, 2015, PLOS ONE CrossRef
7. The G Protein-Coupled Receptor UT of the Neuropeptide Urotensin II Displays Structural and Functional Chemokine Features
   Hélène Castel et al, 2017, Frontiers in Endocrinology CrossRef
8. Urotensin receptor antagonist urantide improves atherosclerosis-related kidney injury by inhibiting JAK2/STAT3 signaling pathway in rats
   Tu Wang et al, 2020, Life Sciences CrossRef
9. Lipidated peptides derived from intracellular loops 2 and 3 of the urotensin II receptor act as biased allosteric ligands
   Hassan Nassour et al, 2021, Journal of Biological Chemistry CrossRef